dokumendiregister.ee
Väljaminev kiriAvalik

Küsimused

Ravimiamet · 18. veebruar 2025
Viit
MSO-13/808-2
Registreeritud
18. veebruar 2025
Dokumendi liik
Väljaminev kiri
Adressaat
IQVIA MedTech
Saabumis/saatmisviis
Outlook
Funktsioon
MSO Meditsiiniseadmed
Sari
MSO-13 Meditsiiniseadmete kliiniliste uuringute ja toimivusuuringute dokumendid (taotlused, load, muud teavitused ja kirjavahetus)
Toimik
MSO-13/2025
Vastutaja
Merili Saar-Abroi (RA, Meditsiiniseadmete osakond)

Failid

Sisu (failidest)

Saatja: RA MSO </O=SOTSIAALMINISTEERIUM/OU=EXCHANGE ADMINISTRATIVE GROUP (FYDIBOHF23SPDLT)/CN=RECIPIENTS/CN=72F3C63240224E00B8EFA069E66B5C58-RA> Saaja: Podolak, Amira, RA MSO Teema: Vs: Publication of data Dear Dr. Podolak State Agency of Medicines does not publish any data regarding medical devices studies submitted for their authorisation. All the best, Merili Saar-Abroi on behalf of Department of Medical Devices State Agency of Medicines [email protected] <mailto:[email protected]> 1 Nooruse Street 50411 Tartu Estonia Phone: +372 737 4140 www.ravimiamet.ee Saatja: Podolak, Amira <[email protected]> Saatmisaeg: neljapäev, 9. jaanuar 2025 12:24 Adressaat: RA MSO <[email protected]> Teema: Publication of data Dear Sirs, I’d like to confirm if the State Agency of Medicines publish any data regarding medical devices studies submitted for their authorization? I’d highly appreciate your feedback regarding this matter. Kind regards, Amira Podolak, Ph.D. Associate Regulatory & Start-Up Manager IQVIA MedTech, Clinical Operations Learn more <http://www.iqviamedtech.com/> about IQVIA MedTech Home Based (Gdynia, Poland) tel. +48 22 430 31 34 Upcoming ooo: 17Feb-28Feb (holidays) ________________________________________ IMPORTANT - PLEASE READ: This electronic message, including its attachments, is CONFIDENTIAL and may contain PROPRIETARY or LEGALLY PRIVILEGED or PROTECTED information and is intended for the authorized recipient of the sender. If you are not the intended recipient, you are hereby notified that any use, disclosure, copying, or distribution of this message or any of the information included in it is unauthorized and strictly prohibited. If you have received this message in error, please immediately notify the sender by reply e-mail and permanently delete this message and its attachments, along with any copies thereof, from all locations received (e.g., computer, mobile device, etc.). To the extent permitted by law, we may monitor electronic communications for the purposes of ensuring compliance with our legal and regulatory obligations and internal policies. We may also collect email traffic headers for analyzing patterns of network traffic and managing client relationships. For further information see our privacy-policy <https://www.iqvia.com/about-us/privacy/privacy-policy> . Thank you.
Allikas: Ravimiamet dokumendiregister →